Evidence map›Paper›PMID 31979113›Full record

ReviewInternational journal of molecular sciences2020

Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent.

Hyeon Su Joo, Ju Hun Suh, Hyeon Ji Lee, Eun Song Bang, Jung Min Lee

2 registry-linked trialsAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05787288 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Study on the Safety and Efficacy of Mesenchymal Stem Cell Exosomes in the Treatment of Coronavirus Infection.

TypeinterventionalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2023 to 2025Enrolled240ConditionsCOVID-19 PneumoniaArmsExtracellular Vesicles from Mesenchymal Stem Cells
NCT05808400 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19 Infection

TypeinterventionalSponsorHuazhong University of Science and TechnologyRan2023 to 2025Enrolled80ConditionsLong COVID-19 SyndromeArmsMSC-derived exosomes
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hyeon Su JooSchool of Life Science, Handong Global University, Pohang 37554, Korea.
Ju Hun SuhSchool of Life Science, Handong Global University, Pohang 37554, Korea.
Hyeon Ji LeeSchool of Life Science, Handong Global University, Pohang 37554, Korea.
Eun Song BangSchool of Life Science, Handong Global University, Pohang 37554, Korea.
Jung Min LeeSchool of Life Science, Handong Global University, Pohang 37554, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are on the cusp of regenerative medicine due to their differentiation capacity, favorable culture conditions, ability to be manipulated in vitro, and strong immunomodulatory activity. Recent studies indicate that the pleiotropic effects of MSCs, especially their immunomodulatory potential, can be largely attributed to paracrine factors. Exosomes, vesicles that are 30-150 nanometers in diameter that function in cell-cell communication, are one of the key paracrine effectors. MSC-derived exosomes are enriched with therapeutic miRNAs, mRNAs, cytokines, lipids, and growth factors. Emerging evidences support the compelling possibility of using MSC-derived exosomes as a new form of therapy for treating several different kinds of disease such as heart, kidney, immune diseases, neural injuries, and neurodegenerative disease. This review provides a summary of current knowledge and discusses engineering of MSC-derived exosomes for their use in translational medicine.

Indexed as

AnimalsExosomesHumansMesenchymal Stem CellsNeurodegenerative DiseasesParacrine CommunicationRegenerative Medicineexosomemesenchymal stem cellpre-conditioningtranslational medicine

Identifiers

PMID31979113
PMCPMC7036914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.